Identification of lactate-related subgroups and prognostic model in triple-negative breast cancer

被引:1
|
作者
Huang, Shan-Shan [1 ]
Wu, Lin-Yu [1 ]
Qiu, Yu [1 ]
Xie, Yi [1 ]
Wu, Hao [1 ]
Li, Ying-Qing [2 ]
Xie, Xin-Hua [1 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Outpatient Dept, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
基金
中国国家自然科学基金;
关键词
Triple-negative breast cancer; Lactate; Prognostic model; Nomogram; MUTATIONS; PEMBROLIZUMAB; CHEMOTHERAPY; METASTASES; FUMARATE; PREDICT;
D O I
10.1007/s00432-023-05171-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTriple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that exhibits elevated glycolytic capacity. Lactate, as a byproduct of glycolysis, is considered a major oncometabolite that plays an important role in oncogenesis and remodeling of the tumor microenvironment. However, the potential roles of lactate in TNBC are not yet fully understood. In this study, our goal was to identify prognosis-related lactate genes (PLGs) and construct a lactate-related prognostic model (LRPM) for TNBC.MethodsFirst, we applied lactate-related genes to classify TNBC samples using a hierarchical clustering algorithm. Then, we performed the log-rank analysis and the least absolute shrinkage and selection operator analysis to screen PLGs and construct the LRPM. The biological functions of the identified PLGs in TNBC were investigated using CCK8 assay and clone formation assay. Finally, we constructed a nomogram based on the lactate-risk score and tumor clinical stage. We used the operating characteristic curve and decision curve analysis to evaluate the predictive capability of the nomogram.ResultsOur results showed that the TNBC samples could be classified into two subgroups with different survival probabilities. Three genes (NDUFAF3, CARS2 and FH), which can suppress TNBC cell proliferation, were identified as PLGs. Moreover, the LRPM and nomogram exhibited excellent predictive performance for TNBC patient prognosis.ConclusionWe have developed a novel LRPM that enables risk stratification and identification of poor molecular subtypes in TNBC patients, showing great potential in clinical practice.
引用
收藏
页码:13107 / 13122
页数:16
相关论文
共 50 条
  • [21] Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
    Kudelova, Eva
    Smolar, Marek
    Holubekova, Veronika
    Hornakova, Andrea
    Dvorska, Dana
    Lucansky, Vincent
    Koklesova, Lenka
    Kudela, Erik
    Kubatka, Peter
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [22] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
  • [23] Identification of disulfidptosis-related clusters and construction of a disulfidptosis-related gene prognostic signature in triple-negative breast cancer
    Wu, Jie
    Cai, Yan
    Zhao, Gaiping
    HELIYON, 2024, 10 (12)
  • [24] Identification of dysregulated microRNAs in triple-negative breast cancer
    Yang, Fang
    Zhang, Wenwen
    Shen, Yan
    Guan, Xiaoxiang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 927 - 932
  • [25] Advances in the systemic treatment of triple-negative breast cancer
    Lebert, J. M.
    Lester, R.
    Powell, E.
    Seal, M.
    McCarthy, J.
    CURRENT ONCOLOGY, 2018, 25 : S142 - S150
  • [26] Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker
    O'Conor, Christopher J.
    Chen, Tiffany
    Gonzalez, Ivan
    Cao, Dengfeng
    Peng, Yan
    BIOMARKERS IN MEDICINE, 2018, 12 (07) : 813 - 820
  • [27] Triple-negative breast cancers
    Narod, Steven A.
    Dent, Rebecca
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1041 - 1043
  • [28] Vimentin as a poor prognostic factor for triple-negative breast cancer
    Nami Yamashita
    Eriko Tokunaga
    Hiroyuki Kitao
    Yuichi Hisamatsu
    Kenji Taketani
    Sayuri Akiyoshi
    Satoko Okada
    Shinichi Aishima
    Masaru Morita
    Yoshihiko Maehara
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 739 - 746
  • [29] Vimentin as a poor prognostic factor for triple-negative breast cancer
    Yamashita, Nami
    Tokunaga, Eriko
    Kitao, Hiroyuki
    Hisamatsu, Yuichi
    Taketani, Kenji
    Akiyoshi, Sayuri
    Okada, Satoko
    Aishima, Shinichi
    Morita, Masaru
    Maehara, Yoshihiko
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (05) : 739 - 746
  • [30] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187